After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Japanese manufacturing activity shrank for a fourth straight month in August as export orders fell at a sharper pace.Asia Marketsread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
The Washington governor had centered his campaign around climate change, calling it "the most urgent challenge of our time."Politicsread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
The sexy image that once boosted Victoria's Secret has been haunting L Brands more recently, as women are steering clear of the brand's hot pink, lacy and bejeweled lingerie.Retailread more
Ford is one of four automakers that reached a voluntary agreement with California on fuel efficiency rules, defying Trump and his administration's effort to strip the state of...Autosread more
See which stocks are posting big moves after the bell.Market Insiderread more
"I'd love to say that the optimistic universe is most likely to prevail, but the talking heads talk endlessly about how a recession is inevitable," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Three years ago, a reporter asked Kadmon Corporation founder Samuel Waksal his opinion on embattled diagnostic start-up Theranos. Recalling the moment on Friday during a "Squawk Box" interview, Waksal said he responded candidly.
"It's a scam," he told the reporter, citing Theranos' refusal to disclose information about its core Edison technology.
In response, the reporter told him he didn't want to believe that was true because Theranos — a potentially transformative start-up led by a woman who dropped out of college — had such a great story.
Waksal told CNBC that thinking was emblematic of the way the media treated Theranos founder Elizabeth Holmes, who claimed her company could conduct a "full range" of medical tests with just a few drops of blood, in the process creating savings for patients and health-care operators alike.
Now, Theranos faces a criminal investigation into whether it misled investors, and inquiries from multiple federal agencies. It has voided two years' worth of results from its Edison machines, and this week, Walgreens ended its relationship with Theranos.
Those developments followed an expose in The Wall Street Journal that put forward evidence the company was not actually conducting many tests on the Edison machines because they were unreliable.
Waksal is himself a notorious figure in the pharma world. The former CEO of biotech firm ImClone was convicted of insider trading in 2003, spent five years in prison and was barred for life from serving as an officer or director of a publicly traded company. Martha Stewart also served jail time for trading on inside information of ImClone.
Waksal said he was skeptical of Theranos' claims from the beginning.
"When you ask someone about science, and they tell you it's a secret, one should run the other way," he said. "In science … even if we leave out minute details, we talk about what science is all about."
For example, Theranos could have explained how it was dealing with DNA to deliver multiple results from a small amount of blood, he said.
Theranos' fall from grace has damaged the pharmaceutical industry, which is often painted with broad strokes, Waksal said.
Earlier this month, Theranos board member and former Wells Fargo CEO Dick Kovacevich told "Squawk Box" he still believes in Theranos' technology. Theranos did not immediately respond to a request for comment.